Confirming the Diagnosis: Tests and Preparation
At a Glance
Narcolepsy type 1 is confirmed by excessive daytime sleepiness plus either sleep-study findings of an average sleep latency of 8 minutes or less and at least two early REM periods, or a CSF hypocretin-1 level of 110 pg/mL or lower. Careful preparation helps avoid misleading results.
Diagnosing Narcolepsy Type 1 (NT1) is a detailed process that goes beyond simply reporting sleepiness. Because the symptoms of NT1 can overlap with many other conditions—like sleep apnea, ADHD, or depression—doctors use specialized tests to look for biological markers of the disorder [1][2][3]. A single negative or borderline study does not necessarily rule out narcolepsy, as results can be influenced by poor sleep hygiene or medications.
The Diagnostic Pathway
The current international criteria (ICSD-3-TR) allow for two main ways to diagnose NT1: the sleep study pathway or the spinal fluid pathway [4]. Both pathways require that you have clinically significant excessive daytime sleepiness and appropriate clinical context [1].
1. The Sleep Study Duo (PSG and MSLT)
This is the most common diagnostic route. It involves two separate but connected tests performed at a sleep center.
- Polysomnography (PSG): You spend the night in the lab while sensors monitor your brain waves, breathing, and muscle movements. The main goals are to ensure you receive an adequate opportunity to sleep, record the minimum required hours of sleep, and rule out other sleep disorders, like Obstructive Sleep Apnea (OSA), which can mimic narcolepsy [3][5].
- Multiple Sleep Latency Test (MSLT): This occurs the day immediately following your PSG. You will be asked to take four or five 20-minute naps scheduled two hours apart. Specialists look for two specific markers:
- Mean Sleep Latency: The average time it takes you to fall asleep across all naps must be 8 minutes or less [1].
- SOREMPs: This stands for Sleep-Onset REM Periods. Most people take about 90 minutes to enter REM (dreaming) sleep, but people with NT1 often enter REM within 15 minutes of falling asleep. To meet the criteria, you must have at least two SOREMPs during the MSLT (a formally identified SOREMP on the previous night’s PSG can often count as one of these two) [1][6].
2. CSF Hypocretin-1 Testing
For some patients, sleep studies may be inconclusive or difficult to perform safely (for example, if a patient cannot safely taper certain psychiatric medications). In these cases, a lumbar puncture (spinal tap) can be performed to measure the level of hypocretin-1 (orexin) in the spinal fluid [7].
- The Threshold: A level of 110 pg/mL or lower is a highly specific biological marker for NT1 [7][4].
- Accuracy: This test is considered very reliable. However, intermediate levels (between 111 and 200 pg/mL) are less clear. Intermediate results are not independently diagnostic of early-stage NT1 and require expert interpretation [8][9]. A lumbar puncture is not a simple substitute for every patient, and you should discuss its availability, risks, and clinical limitations with your specialist.
Essential Pre-Test Preparation
To get an accurate result, your brain must be in its “natural” state during the MSLT. This requires careful preparation under a doctor’s supervision:
- Documenting Sleep Habits: You will likely be asked to keep a sleep diary or wear an actigraphy device (a specialized wrist monitor) for 1 to 2 weeks before the study [10][11]. This helps prove that you are maintaining a regular sleep schedule and that your daytime sleepiness is not simply caused by “insufficient sleep syndrome” or circadian misalignment [12][13].
- Medication Washout (⚠️ CAUTION): Many common medications, especially SSRIs or SNRIs (antidepressants) and stimulants, strongly suppress REM sleep or mask sleepiness. Your sleep doctor may want you to stop these before the test to avoid a “false negative.” However, you must NEVER stop or taper antidepressants, stimulants, or other psychiatric medications on your own without direct supervision from your prescribing team. Abruptly stopping can lead to dangerous withdrawal, a relapse of severe depression or suicidality, or severe rebound cataplexy [10][14]. The washout duration varies by drug; if a washout is unsafe, your clinician may modify the testing plan.
Ruling Out “Look-Alikes”
Because “being tired” is a symptom of many things, doctors must rule out several common misdiagnoses:
- Obstructive Sleep Apnea (OSA): Apnea can cause severe daytime sleepiness and even lead to SOREMPs on an MSLT. In some cases, once the apnea is treated (with CPAP, for example), the “narcolepsy” patterns on the sleep test resolve [3][15].
- ADHD: The struggle to focus caused by sleepiness is often mistaken for ADHD, especially in children [2].
- Depression: The lack of energy and “dream-like” hallucinations in NT1 can sometimes be mislabeled as a primary psychiatric disorder [16].
Common questions in this guide
How is narcolepsy type 1 usually diagnosed?
What do the overnight sleep study and MSLT measure?
Can sleep apnea make an MSLT look like narcolepsy?
What does a low CSF hypocretin-1 result mean?
How should I prepare for narcolepsy testing?
Is it safe to stop antidepressants or stimulants before an MSLT?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What was my mean sleep latency on the MSLT, and how many SOREMPs did I have?
- 2.Since my overnight study (PSG) showed some sleep apnea, how do we know the sleepiness during my MSLT was from narcolepsy and not from the apnea?
- 3.Was a SOREMP recorded during my overnight study, and how did that affect my diagnosis?
- 4.If I cannot safely stop my antidepressant or other medications, can we use a lumbar puncture for CSF testing instead of the MSLT?
- 5.Based on my actigraphy or sleep logs, was I getting enough sleep in the weeks leading up to the test to ensure the results are accurate?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (16)
- 1
The ICSD-3 and DSM-5 guidelines for diagnosing narcolepsy: clinical relevance and practicality.
Ruoff C, Rye D
Current medical research and opinion 2016; (32(10)):1611-1622 doi:10.1080/03007995.2016.1208643.
PMID: 27359185 - 2
Narcolepsy and psychiatric comorbidity: a review of the literature.
Verstraete L, Van Den Bossche M
International journal of clinical and health psychology : IJCHP 2025; (25(2)):100591 doi:10.1016/j.ijchp.2025.100591.
PMID: 40546276 - 3
A false alarm of narcolepsy: obstructive sleep apnea masquerading as narcolepsy and depression.
Paudel D, Lin Q, Yan C, et al.
Sleep & breathing = Schlaf & Atmung 2019; (23(3)):873-877 doi:10.1007/s11325-018-1767-7.
PMID: 30523556 - 4
Narcolepsies, update in 2023.
Barateau L, Pizza F, Chenini S, et al.
Revue neurologique 2023; (179(7)):727-740 doi:10.1016/j.neurol.2023.08.001.
PMID: 37634997 - 5
Test-retest repeatability of the multiple sleep latency test in non-cataleptic hypersomnolence disorders.
Johnson J, Grigg-Damberger M, El Ahdab J, et al.
Sleep medicine 2026; (142()):108876 doi:10.1016/j.sleep.2026.108876.
PMID: 41780441 - 6
[NARCOLEPSY WITH CATAPLEXY: TYPE 1 NARCOLEPSY].
Dauvilliers Y, Lopez R
La Revue du praticien 2016; (66(6)):671-6.
PMID: 27538328 - 7
To diagnose narcolepsy type 1 after a negative multiple sleep latency test: the contribution of systematic hypocretin measurement.
Biscarini F, Vandi S, Neccia G, et al.
Sleep 2026; (49(9)) doi:10.1093/sleep/zsag142.
PMID: 42189945 - 8
Intermediate hypocretin-1 cerebrospinal fluid levels and typical cataplexy: their significance in the diagnosis of narcolepsy type 1.
van der Hoeven AE, Fronczek R, Schinkelshoek MS, et al.
Sleep 2022; (45(5)) doi:10.1093/sleep/zsac052.
PMID: 35554594 - 9
Progressive narcolepsy: how to deal with intermediate hypocretin-1 values?
Ricordeau F, Bridoux A, Raverot V, Peter-Derex L
Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2023; (19(7)):1375-1378 doi:10.5664/jcsm.10576.
PMID: 37066739 - 10
Narcolepsy type 2: A rare, yet existing entity.
Baumann-Vogel H, Schreckenbauer L, Valko PO, et al.
Journal of sleep research 2021; (30(3)):e13203 doi:10.1111/jsr.13203.
PMID: 32989797 - 11
Sleep schedules and MSLT-based diagnosis of narcolepsy type 2 and idiopathic hypersomnia: Exploring potential associations in a large clinical sample.
Matsui K, Usui A, Takei Y, et al.
Journal of sleep research 2025; (34(3)):e14402 doi:10.1111/jsr.14402.
PMID: 39533540 - 12
Clinical and instrumental comparison between insufficient sleep syndrome and narcolepsy type 1.
Manconi M, Castelnovo A, Miano S, De Pieri M
Sleep medicine 2026; (138()):108720 doi:10.1016/j.sleep.2025.108720.
PMID: 41411879 - 13
Diagnosing narcolepsy in the active duty military population.
Villarreal B, Powell T, Brock MS, Hansen S
Sleep & breathing = Schlaf & Atmung 2021; (25(2)):995-1002 doi:10.1007/s11325-020-02163-5.
PMID: 33629215 - 14
Sleep-stage transitions during polysomnographic recordings as diagnostic features of type 1 narcolepsy.
Christensen JA, Carrillo O, Leary EB, et al.
Sleep medicine 2015; (16(12)):1558-66.
PMID: 26299470 - 15
Prevalence and Clinical Correlates of a Short Onset REM Period (SOREMP) during Routine PSG.
Cairns A, Bogan R
Sleep 2015; (38(10)):1575-81 doi:10.5665/sleep.5050.
PMID: 26039966 - 16
Temporal patterns of sleep latency in central hypersomnia and attention deficit hyperactivity disorder: a cluster analysis exploration using Multiple Sleep Latency Test.
Maruo T, Takagi S, Uchida S, et al.
Frontiers in psychiatry 2024; (15()):1361140 doi:10.3389/fpsyt.2024.1361140.
PMID: 38544845
This page explains how narcolepsy type 1 is evaluated and how to prepare for testing; it is for information only and does not replace medical advice. Do not change medications without guidance from your prescribing and sleep-care teams.
Get notified when new evidence is published on narcolepsy 1.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.